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Abstract
Growth hormone (GH) diminishes adipose tissue mass in vivo and prolactin (PRL) can also modulate adipocyte metabolism. Both
GH and PRL are potent activators of STAT5 and exert a variety of effects on adipocyte gene expression. In this study, we have dem-
onstrated that GH and PRL increase the mRNA of acyl CoA oxidase in 3T3-L1 adipocytes. We also identified seven putative STAT
elements in the murine AOX promoter. We observed that GH modulates protein binding to the majority of these promoter elements.
However, GH induced very potent binding to 1841 to 1825 of the murine AOX promoter. EMSA supershift analysis revealed that
this site was specifically bound by STAT5A, but not by STAT1 or STAT3. Taken together, these data strongly suggest that GH directly
induces the expression of AOX in adipocytes through STAT5A binding to the 1841 to 1825 site within the AOX promoter. Our
observations are consistent with other studies that demonstrate that STAT5 activators modulate fatty acid oxidation.
 2006 Elsevier Inc. All rights reserved.
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Growth hormone (GH) is known to have profound
effects on lipid metabolism [1]. The effects of PRL have
been well characterized in mammary tissues, yet there is
also evidence demonstrating that this hormone can affect
adipose tissue in mice and humans [2,3]. However, few
direct molecular targets for the actions of GH and PRL
on adipocyte metabolism have been identified. It is well
known that GH and PRL induce signaling via the JAK-
STAT pathway. In particular, STAT 5 proteins are potent-
ly activated by these two hormones [4]. Also, multiple lines
of evidence suggest that STAT5 proteins can modulate adi-
pocyte function.
During differentiation of 3T3-L1 adipocytes, the
expression levels of STAT5A and 5B are highly induced
[5] and GH dependent adipogenesis of 3T3-F442A cells
is attenuated by STAT5 anti-sense oligonucleotides [6].
Also, constitutively active STAT5 can replace the
requirement for GH in adipogenesis of these cells [7].
Moreover, ectopic expression of STAT5A has been
shown to confer adipogenesis in 3T3-L1 preadipocytes
[8] and in two different non-precursor cell lines [9].
Transgenic deletion of STAT5A, STAT5B, or both
STAT5 genes in mice results in significantly reduced fat
pad sizes compared to wild-type mice [10], further evi-
dence that STAT proteins play a role in adipogenesis.
Yet, in primary cultures of adipose tissue from these ani-
mals, GH did not stimulate lipolysis as it does in adipo-
cytes from wild-type animals [11], suggesting that some
of the effects of GH on fat metabolism in mature adipo-
cytes also are dependent on STAT5 proteins. However,
very few studies have identified specific direct STAT5
target genes in adipocytes. We recently observed that
the GH and PRL inhibition of fatty acid synthase tran-
scription was mediated by a STAT5A binding site in the
rat FAS promoter [12]. Hence, our current efforts have
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been to identify other genes associated with fatty acid
metabolism that are directly modulated by STAT5 pro-
teins in fat cells.
In this study, we examined the modulation of acyl CoA
oxidase (AOX), a rate-limiting enzyme in peroxisomal fatty
acid oxidation. This is the first study to demonstrate that
both GH and PRL modulate AOX expression in fat cells.
Moreover, we identified seven STAT elements in the
AOX promoter and demonstrated that binding to these
sites was modulated by GH. Finally, our in vitro studies
have demonstrated that the specific binding to the 1841
to 1825 site in the murine AOX promoter is mediated
by STAT5A.
Materials and methods
Materials. Dulbecco’s modified Eagle’s medium (DMEM) and fetal
bovine serum (FBS) were purchased from Invitrogen. STAT1 antibody
was purchased from Upstate Biotechnology. STAT3 and STAT5A anti-
bodies were purchased from Santa Cruz. Porcine growth hormone (GH)
and ovine prolactin (PRL) were purchased from Sigma. Taqman RT-PCR
reagent mix was from Applied Biosystems and fluorescent Taqman probes
(FAM/BHQ) were purchased from Biosearch Technologies. [a-32P]dCTP
and deoxynucleotides were purchased from Amersham. Klenow fragment
was from Promega.
Cell culture. Murine 3T3-L1 preadipocytes were plated and grown to 2
days post confluence in DMEM with 10% bovine serum. Medium was
changed every 48 h. Cells were induced to differentiate by changing the
medium to DMEM containing 10% fetal bovine serum, 0.5 mM 3-isobu-
tyl-1-methylxanthine, 1 lM dexamethasone, and 1.7 lM insulin. This
medium was replaced with DMEM containing 10% fetal bovine serum and
425 nM insulin for 48 h. Adipocytes were then maintained in DMEM with
10% fetal bovine serum for at least eight days. Adipocytes were serum
deprived in DMEM with 0.15% BSA overnight before treatment with GH
or PRL.
Nuclear and cytosolic extract preparation. Monolayers of 3T3-L1 adi-
pocytes were harvested in a nuclear homogenization buffer (NHB) as
described [13]. Nonidet P-40 was added to a final concentration of 0.15%,
and cells were homogenized with 16 strokes in a Dounce homogenizer.
Homogenates were centrifuged at 1500 rpm for 6 min at 4 C. The
supernatants were saved and frozen as cytosolic extracts and the pellets of
intact nuclei were resuspended in half of the previous volume of NHB and
centrifuged as before. The pellet of intact nuclei was resuspended in a
buffer of 20 mM Hepes, pH 7.9, 0.42 M NaCl, 1.5 mM MgCl2, 0.2 mM
EDTA, and 25% glycerol. For electromobility shift assays, the nuclear
extracts were incubated on ice for at least 30 min and then drawn twice
through a 20 gauge needle. Nuclei were centrifuged for 10 min at
10,000 rpm and the supernatants were taken for protein analysis by BCA
or stored in aliquots at 80 C.
Electromobility shift assays. Annealed, double-stranded oligonucleo-
tides with GG overhangs were end labeled by a fill-in reaction using DNA
polymerase I Klenow fragment in the presence of [a-32P]dCTP as descri-
bed in detail [14]. End-labeled oligonucleotides were purified from unin-
corporated [32P]dCTP with Bio-Rad Micro Biospin-6 chromatography
columns. Cytoplasmic or nuclear extracts (15 lg) were incubated with 2 ll
of end-labeled oligonucleotides (50,000 cpm/ll) for 30 min on ice prior to
loading on a gel that had been pre-run for 30 min as described [12]. For
cold competition analysis to determine specificity of binding, nuclear
extracts were incubated on ice for 15 min with unlabeled oligo before
addition of [32P]-labeled probe. For supershift analysis, nuclear extracts
were preincubated with antibody for one hour at room temperature.
Total RNA extraction and expression analysis. Total RNA was isolated
from 3T3-L1 adipocyte monolayers using Trizol (Life Technologies)
according to manufacturer’s protocols. Total RNA was diluted in water
and 14 ng was used per 30 lL RT-PCR mixture to quantitatively
determine AOX and cyclophilin B mRNA levels using an Applied Bio-
systems Prism 7000 sequence detection system. Taqman probes and
primers were designed with Primer Express software (ABI). Relative val-
ues of target gene mRNAs were quantitated from a standard curve and
adjusted for total RNA per PCR using cyclophilin B. mRNA values are
expressed as means ± standard error of the mean. Sequences of primers
and probes are as follows: acyl CoA oxidase1 forward primer CAGCCAG
ATTGGTAGAAATTGCT, reverse primer ACGCCACTTCCTTGC
TCTTC, and probe CAAAAAACCTTCAGGCCCAAGTGAGTCAC;
cyclophilin B forward primer GGTGGAGAGCACCAAGACAGA,
reverse primer GCCGGAGTCGACAATGATG, and probe ATCCTTC
AGTGGCTTGTCCCGGCT.
Results
STAT5 activators induce acyl CoA expression in 3T3-L1
adipocytes
Mature 3T3-L1 adipocytes were treated with either
growth hormone or prolactin and Taqman quantitative
RT-PCR was performed to determine mRNA levels of acyl
CoA oxidase (AOX). As shown in Fig. 1, AOX mRNA was
readily detectable in untreated 3T3-L1 adipocytes, but
treatment with either GH or PRL resulted in a significant
increase in AOX mRNA levels within 30 min. In GH treat-
ed adipocytes, the levels of AOX mRNA started to
decrease within an hour, but in PRL treated cells AOX
mRNA levels did not decline to the same extent.
The identification of STAT binding sites in the AOX
promoter
Since GH and PRL are potent STAT activators, we
hypothesized that the AOX promoter may be modulated
by these transcription factors. An analysis of the first
2000 base pairs of the promoter revealed seven putative
STAT sites (Table 1). We performed electrophoretic mobil-
ity shift assays (EMSAs) using nuclear extracts from GH
treated 3T3-L1 adipocytes and labeled DNA binding sites
to determine if GH induced binding to any of these consen-
sus sites. As shown in Fig. 2, we observed GH dependent
binding to the 1841 element. A darker exposure of this
blot revealed GH regulated binding to four other STAT
elements at 1362, 1466, 1479, and 1998. Although
there was protein binding at the other 2 sites (561 and
1978), this interaction was not substantially regulated
by GH (bottom panel, Fig. 2). These data demonstrate that
five of the seven STAT elements in the AOX promoter bind
nuclear adipocytes proteins in a GH dependent manner
in vitro.
Since the 1841 element of the AOX promoter
appeared to have a substantial amount of protein bound,
we further examined protein binding to this element. To
examine the specificity, we performed EMSAs with cytosol-
ic extract and nuclear extracts from GH treated 3T3-L1
adipocytes. As shown in Fig. 3A, we only observed binding
to the STAT element when samples were incubated with
nuclear extracts from GH treated cells, but no binding
was observed with cytosolic extract from GH treated
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adipocytes. Also, GH regulated protein binding to labeled
oligonucleotides corresponding to 1841 to 1825 of the
AOX promoter was effectively competed with unlabeled
wild-type oligonucleotides. As shown in the EMSA in
Fig. 3A, the STAT site was only bound by nuclear proteins
and not by cytosolic proteins. To determine what STAT
proteins comprised the bound complex, we performed
supershift analysis with antibodies directed against three
different STAT proteins that are expressed in fat cells. As
shown in Fig. 3B, the GH sensitive protein complex was
completely supershifted by an antibody directed against
STAT5A, but was unaffected by STAT1 or STAT3
antibodies.
Discussion
The novel findings in this study include data demon-
strating that AOX levels are increased following stimula-
tion with activators of STAT5 in 3T3-L1 adipocytes, the
identification of several GH responsive regions in the mur-
ine AOX promoter, and the characterization of a STAT5A
binding site in the AOX promoter. These results suggest
that STAT5A directly modulates the expression of AOX
in adipocytes. Moreover, our data suggest that STAT5A
has catabolic functions in murine adipocytes, in addition
to its adipogenic and lipogenic capabilities that have been
previously been described [7,9].
GH and prolactin (PRL) are potent activators of
STAT5 and exert adipogenic effects in preadipocytes. In
vivo administration of GH induces lipolysis and lipid oxi-
dation in adipose tissue. Both mitochondria and peroxi-
somes carry out fatty acid b-oxidation. The first step of
peroxisomal b-oxidation is catalyzed by acyl-CoA oxidase
(AOX). Acyl-CoA oxidase mRNA and protein expression
is most abundant in liver followed by kidney, brain, and
adipose tissue [15]. Mice lacking AOX have steatohepatitis,
spontaneous peroxisome proliferation, and liver tumors
[16]. Other studies in AOX deficient mice have revealed
that substrates of this enzyme function as ligands for
PPARa and play a role in hepatic lipid metabolism and
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Fig. 1. Growth hormone and prolactin rapidly induce AOX mRNA in 3T3-L1 adipocytes. Total RNA was isolated from fully differentiated 3T3-L1
adipocytes that were treated for the indicated times with 125 ng/ml growth hormone (GH) or 1 IU/ml of prolactin. The levels of mRNA expression were
determined by quantitative RT-PCR using Taqman probes and primers. Values shown represent mean values of target mRNA per cyclophilin B
mRNA ± SE from two independent experiments performed at least in triplicate. Stars indicate a significant difference from control values as determined
by Anova single factor analysis with p < 0.01.
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Fig. 2. GH induces binding to putative STAT elements located within the
first 2000 bases upstream of the murine AOX promoter. Nuclear extracts
were prepared from adipocytes that were untreated () or treated (+) with
125 ng/ml GH for 15 min and protein–DNA complexes were resolved by
EMSA. For each sample, 15 lg of protein was incubated with
100,000 cpm of the indicated [32P]-labeled probes. A darker exposure of
the gel is shown in the lower panel. This is a representative experiment
independently performed three times.
Table 1
STAT sites in the AOX promoter
Site Location Sequence
1 (561 to 541) TTTGGGTTCCAGTAAAATCAA
2 (1362 to 1346) TTTTTTCGAGACAGGGT
3 (1466 to 1448) ACCCATTCTCAGCACCGTT
4 (1479 to 1461) CTTCATTCGTTTAACCCAT
5 (1841 to 1825) TAACTTCTCAGAATTTT
6 (1998 to 1980) CAAGCTTCTGCTAAGAGGA
7 (1978 to 1959) TAAAATTCACAAGAACCCAA
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To date, very little is known about the modulation of
AOX expression. The promoter regions of the acyl-CoA
oxidase contain transcriptional regulatory peroxisome pro-
liferator-response elements (PPREs) [18] which likely medi-
ate the increase in AOX mRNA that is induced by
bezafibrate and accompanied by peroxisomal b-oxidation
in white adipose tissue in rats [19]. ACO mRNA levels have
also been shown to be modulated in GH transgenic mice
[20]. Besides the PPARa site and the STAT sites that we
identified, there has been little characterization of other
regulatory elements in the AOX promoter.
There are various studies demonstrating that both GH
and PRL play a role in adipose tissue development [21]
and we have known for decades that growth hormone
is a potent regulator of lipid metabolism [1]. However,
few direct molecular targets of GH have been identified
in fat cells. It is well documented that GH can attenuate
fatty acid synthesis and enhance fatty acid oxidation.
Our recent studies have shown that the GH induced inhi-
bition of fatty acid synthase expression can be mediated
by STAT5A binding to the FAS promoter [12]. In this
study, we have shown that STAT5A can also modulate
the expression of an enzyme involved in fatty acid oxida-
tion. In conclusion, we hypothesize that STAT5 proteins
are important regulators of various genes associated with
lipid metabolism.
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Fig. 3. The specific GH induced binding to 1841 to 1825 of AOX promoter is mediated by STAT5A. (A) Nuclear extracts were prepared from
adipocytes that were untreated or treated with 125 ng/ml GH for 15 min and protein–DNA complexes were resolved by EMSA. To demonstrate
specificity, nuclear extracts were preincubated with an excess of the indicated unlabeled oligonucleotides (cold competitor). (B) For each sample, 15 lg of
protein was preincubated with 4 lg of the indicated antibody and then incubated with a [32P]-labeled probe comprising 1841 to 1825 of the AOX
promoter. The protein–DNA complexes were resolved by EMSA. This is a representative experiment independently performed two times.
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